Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Dickens

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2017
Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1Wendy Landier, Lindsey Hageman, Yanjun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology groupSmita Bhatia, Wendy Landier, Muyun Shangguan, et al.
Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
JNCI Cancer Spectrum|April 16, 2025
Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemiaJulie A Wolfson, Allison C Grimes, Michelle M Nuño, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Blood|April 7, 2025
Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemiaSara K Silbert, Alexander W Rankin, Chloe N Hoang, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2017
Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1Wendy Landier, Lindsey Hageman, Yanjun Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2012
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology groupSmita Bhatia, Wendy Landier, Muyun Shangguan, et al.
Nature|March 16, 2023
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaGhayas C Issa, Ibrahim Aldoss, John DiPersio, et al.
JNCI Cancer Spectrum|April 16, 2025
Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemiaJulie A Wolfson, Allison C Grimes, Michelle M Nuño, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Blood|April 7, 2025
Project EVOLVE: An international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemiaSara K Silbert, Alexander W Rankin, Chloe N Hoang, et al.
Pageof 4